Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

PureTech Health PLC

PRTC.L ✗ NOT COMPLIANT ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Small Cap Analyst: STRONG BUY

Last Close

$1.65

▲ +2.02%

Market Cap $405.02M · Vol 1.30M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$405.02M

Small Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

+11.28%

YoY

RSI (14)

61.21

Momentum

Beta

1.28

vs Market

52W High

$1.96

14.66% below

52W Low

$1.43

16.56% above

Volume

1.30M

Avg 640.72K

P/B

1.30

Price-to-book

ROE

-39.81%

Return on equity

Free Float

89.25%

Public shares

Shariah Compliance8 STANDARDS

✗ PureTech Health PLC (PRTC.L) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PRTC.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.66%

-1.46%

-11.92%

-2.57%

YTD

-3.04%

-12.55%

-29.13%

-63.22%

Financials & Valuation

TTM · Annual

Total Revenue	$4.66M
Net Income	$-110,085,000.00
Revenue Growth (YoY)	-38.15%
Gross Margin	100.00%
Operating Margin	-2,114.77%
Net Profit Margin	-2,362.82%
ROE	-39.81%
ROA · ROIC	-19.51% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	87.04
P/B	1.30
P/FCF	N/A
EPS Growth	+11.28%
Outstanding Shares	245.18M

Technical Indicators

50-Day SMA	$1.68
200-Day SMA	$1.72
RSI (14)	61.21
Beta	1.28
52-Week High	$1.96
52-Week Low	$1.43

Volume Today	1.30M
Avg Daily Volume (30D)	640.72K
Relative Volume	2.03x
Volatility (10D)	28.56
Volatility (30D)	26.62
Free Float	89.25%

Analyst Consensus

STRONG BUY

Current Price $1.65

Mean Target $4.91

52W Low$1.43 52W High$1.96

Current

Target

$1.43 $1.96

Current Analyst target

+196.79% upside potential · 3 analysts

Identifiers

ExchangeLSE

FIGIBBG00Y6FM5N4

ISINGB00BY2Z0H74

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.02% ONC BeOne Medicines AG +1.18% RVMD Revolution Medicines Inc -0.09% 068270.KS Celltrion Inc -2.27% ABVX Abivax SA +1.53%

Company Profile

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.